Thousand Oaks, CA, United States of America

Osama Suleiman

This inventor holds 1 USPTO granted patent. Top assignees: Amgen Inc., Cytokinetics, Inc.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Osama Suleiman. Retrieved from https://idiyas.com/inventor/osama-suleiman-y0z7wqdc

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Osama Suleiman

Introduction

Osama Suleiman is an accomplished inventor based in Thousand Oaks, California. He has made significant contributions to the field of cardiac health through his innovative research and development.

Latest Patents

Suleiman holds a patent for "Polymorphs and cocrystals of a cardiac troponin activator." This patent includes free base crystalline forms, crystalline salts, solvates, amorphous free base, and cocrystals of Compound A. His work in this area is crucial for advancing cardiac treatments.

Career Highlights

Throughout his career, Suleiman has worked with notable companies such as Amgen Inc. and Cytokinetics, Inc. His experience in these organizations has allowed him to collaborate with leading experts in the field.

Collaborations

Some of his coworkers include Stephanie Azali and Mary Chaves. Their collective efforts have contributed to the success of various projects in the realm of cardiac health.

Conclusion

Osama Suleiman's innovative work and patent in cardiac health exemplify his dedication to improving medical treatments. His contributions are valuable to the ongoing advancements in this critical field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…